Consonance Capital Management’s Stemline Therapeutics STML Stock Holding History
Bought
Maintained
Sold
Other funds holding STML
Consonance Capital Management's STML Position: Q1 2019 in Review
Consonance Capital Management sold out of Stemline Therapeutics (STML) in Q1 2019, closing a stake of 1,155,793 shares — an estimated $11M sold.
Consonance Capital Management first reported a position in STML in Q3 2017 and held it in 6 quarters. The position peaked at $45.6M in Q3 2018. 98 funds tracked by Wall St. Rank hold STML as of Q1 2019.
- Consonance Capital Management reported no remaining Stemline Therapeutics position as of Q1 2019 after selling out during the quarter.
- Consonance Capital Management sold 1,155,793 Stemline Therapeutics shares in Q1 2019, an estimated $11M.
- Consonance Capital Management first reported a position in Stemline Therapeutics in Q3 2017 and held it in 6 quarters.
- Consonance Capital Management's Stemline Therapeutics position peaked at $45.6M in Q3 2018.
- 98 funds tracked by Wall St. Rank held Stemline Therapeutics as of Q1 2019.
Based on Consonance Capital Management's 13F filing for Q1 2019, filed 15 May 2019.